SUMMARY BackgroundAt present, the efficacy of proton pump inhibitor-clarithromycin-amoxicillin regimen is relatively low.

Empirical 10-day concomitant therapy achieves good eradication rates, close to 90%, in settings with multiresistant H. pylori strains. Tailored concomitant therapy is significantly superior to triple therapy for clarithromycin-susceptible H. pylori and at least as effective as sequential therapy for resistant strains.

SUMMARY BackgroundHelicobacter pylori eradication rates with standard triple therapy have declined to unacceptable levels.

No abstract

No abstract